利伐沙班对静脉血栓好吗

(Rivaroxaban) is a direct inhibitor of factor

In order to study the clinical effect of rivaroxaban on the prevention and treatment of deep vein thrombosis (DVT) after severe traumatic brain injury (sTBI), a domestic study collected 157 sTBI patients who met the inclusion criteria, including 119 male patients (75.8%), aged (38.75±11.98) years old. All patients were treated with intermittent intravenous pneumatic compression to prevent DVT, and D-dimer dynamic monitoring and regular ultrasound examination were used to screen for DVT. If the intracranial hemorrhage was stable, those whose D-dimer continued to decline 3 days after surgery and had high-risk factors were given prophylactic oral rivaroxaban. Patients with confirmed DVT were given therapeutic oral rivaroxaban. Rivaroxaban was discontinued when the conditions for discontinuation were met. The patients' general information, dynamic changes in D-dimer, incidence of DVT, application of rivaroxaban and anticoagulant bleeding complications were retrospectively analyzed.

The results showed that no DVT was found by ultrasound in any of the patients whose D-dimer continued to decrease. There were 45 cases where D-dimer continued not to decrease or increased, and DVT was found in 43 cases by ultrasound. Rivaroxaban was used prophylactically in 47 cases (29.9%) for 7 to 36 days (16.3±6.5), and no DVT occurred during the follow-up period. In 43 cases (27.4%), rivaroxaban was used therapeutically for 32 to 68 days (49.3±9.9) days. Only one case of peripheral DVT recurred after drug withdrawal. There were no symptomatic pulmonary embolism and fatal bleeding complications. There were 3 cases of hematuria, 1 case of tracheotomy bleeding, and 1 case of hemorrhoids causing bloody stools. No increase in intracranial bleeding or other gastrointestinal bleeding was seen.

It can be seen that patients can safely and effectively prevent and treat DVT after sTBI by applying anticoagulation (i.e., Xarelto).

Recommended hot articles: /newsDetail/73106.html